This was an observational survey study administered to individuals over age 18 who identify themselves as having cluster headache. Patient perspectives on the use of placebo in cluster headache clinical trials were assessed using a paper-based survey. Participants were recruited during a national conference held for patients with cluster headaches (“Clusterbusters” in Austin, TX, September 2016). Informed consent was obtained and no identifiable data were collected.
Previous functional and structural imaging studies have revealed that subcortical structures play a key a role in pain processing. The recurring painful episodes might trigger maladaptive plasticity or alternatively degenerative processes that might be detected by MRI as changes in size or microstructure. In the current investigation, we aimed to identify the macro- and microstructural alterations of the subcortical structures in episodic cluster headache.
Patients with CH often require a multimodal treatment approach during cluster periods using acute, transitional, and prophylactic therapy. Transitional therapies are useful in treating high frequency cluster headache attacks while prophylactic medication dosages are increased. However, there is limited data comparing the efficacy of oral versus injected transitional treatments.
Chronic Cluster Headache (CCH) is the most severe and disabling primary headache. Studies using functional magnetic resonance imaging showed the ipsilateral posterior hypothalamus activation during the cluster headache episodes. The Deep Brain Stimulation (DBS) of the posterior hypothalamic area was introduced in 2000 in order to treat drug-resistant chronic cluster headache.
This retrospective observational study analyzed claims data from the Truven Health Analytics MarketScan® Research Databases from 2009–2014. Two cohorts were compared: propensity-score (PS) matched CH and non-headache control patients. Eligible CH patients had ≥2 CH claims. All patients had continuous enrollment for ±12 months from date of first CH claim. Descriptive comparisons are presented.
We screened patients with cluster headache who were diagnosed at Samsung Medical Center and lost to follow-up for ≥5 years. Eligible patients were interviewed by phone about the longitudinal changes in headache characteristics and disease course. Remission was defined as symptom-free 1) for longer than twice the longest between-bout period and 2) for ≥5 years.